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Abstract
Image guided technique is playing an increasingly important role in the investigation of the
biodistribution and pharmacokinetics of drugs or drug delivery systems. The application of
these new materials and techniques with combined properties of diagnosis and therapy can
benefit the development of targeted drug delivery system and modern personalized medicine
This special issue provides an up-to-date collection of original research articles and review on
the development of novel targeted drug and drug delivery systems combining with
non-invasive image guided techniques for chemotherapeutic reagents or DNA delivery.
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Many routinely used therapeutic agents suffer
from properties of poor pharmacokinetics and inappropriate biodistribution. After trying various different passively and actively targeted delivery strategies
over the years, the efficient delivery of a drug to its
designated site of action is still facing challenges, especially in cancer chemotherapy, DNA or protein delivery. For example, because of the low molecular
weight, drugs are rapidly cleared out from circulation;
since the high hydrophobicity, many drugs cannot
show therapeutic efficacy. The unwanted non-target
accumulation and toxicity towards normal tissue are
other major concerns. According to the classic research procedure for a drug delivery development,
scientists are supposed to initiate the studies from
material screening, in vitro testing, and then move
forward to in vivo (pre-clinical) measurement and
further clinical trials. Due to the absence of an effective and accurate tool for monitoring, many agents
which are shown to be highly effective in vitro are

often relatively ineffective when administered in vivo,
sometimes they also tend to be relatively toxic and
have unfavorable biodistribution properties. Moreover, the delay to track the features of a drug makes it
difficult to monitor the drug fate under the physiological circumstance.
Image guided drug delivery (IGDD) is a novel
strategy that combines the effect of therapy and visibility in the drug delivery system to overcome the
above limitations. The term of “Theranostics” encompasses two distinct characteristics, with both
therapeutic and diagnostic agents on a single platform. Such a theranostic system can be used to localize therapeutic targets and monitor drug delivery in a
visible way, therefore improve the therapeutic index
and decrease systemic toxicity. The introduction of
IGDD concept into pharmaceutical sciences will definitely speed up the research on drug R&D with an
extremely high efficiency. This comprehensive IGDD
system combining the properties of both therapy and
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diagnosis possesses numerous advantages over existing treatment approaches. With the assistance from
the development of novel materials, molecular imaging probes for positron emission tomography (PET),
single-photon emission computed tomography
(SPECT), highly sensitive ultrasound, magnetic resonance imaging (MRI), luminescence/fluorescence and
Raman, photoacoustic imaging as well as multimodal
imaging probes can be incorporated with drugs or
drug carriers, facilitating the localization and quantification of radioisotope, optical probe, or other
tag-labeled drug delivery systems in the category of
theranostics. The variety of medical imaging tracking
modalities will help in the development of highly
effective delivery systems for site-specific treatment in
a minimally invasive way, leading to enhanced understanding of cancer biology, disease mechanism
and paths for their eradication.
This special IGDD issue consists of five original
research papers and one review, which are all contributed from leading prominent researchers with
international reputation in the field of theranostics.
The findings include the synthesis and structure
modification of the biomaterials such as chitosan,
PLGA as well as the preparation of emulsions and
liposomes etc., more importantly, the development of
these delivery systems incorporating highly sensitive
image modalities such as X-rays, ultrasound, fluorescence and so on.
The review of “Image guided biodistribution
and pharmacokinetic studies of theranostics” gave an
overall introduction of several existing imaging modalities that had been applied in the field of biomedicine and even in clinics, including MRI, CT, PET,
SPECT, US and fluorescence imaging. And these
quantitative or semi-quantitative imaging modalities
can employ high sensitive image techniques to find
out biodistribution of the labeled drugs or probe
loaded delivery systems in the body. These
non-invasive imaging modalities, including MRI, radio-labeling and fluorescence etc attracted more attention because of their properties of no breaking in
the skin and no contact with the mucosa and no
breaking through internal body cavity beyond a natural or artificial body orifice. This review also listed
some representative applications of imaging modalities in the area of biodistribution and pharmacokinetics of drug delivery system for the aim of treatment
and diagnosis. [1] Dr. Yuan et al. applied low molecular weight hydroxyethyl chitosan-prednisolone
conjugate (LMWHC-Pre, molecular weight 31k Da)
with excellent stability and physicochemical properties for renal targeting therapy. From the help of fluorescence and X-rays, the in vivo results showed sig-
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nificant accumulation of LMWHC-Pre in the area of
kidneys.[2] In Dr. Agata’s work, three molecular
weights of PLGA were chosen for in situ formation of
implants (ISFIs) which could be used for drug delivery applications. With the help of ultrasound based
3-D images, this study demonstrated that implant
properties such as phase inversion, erosion, swelling
and drug release could be tailored by altering the
molar ratio of the polymers used in the depot formulation. [3] Dr. Willmann and his colleagues applied
US-mediated gene delivery (UMGD) to murine
hindlimb skeletal muscle using cationic versus neutral
microbubbles (MBs). The in vivo data showed the
prominent advantage of cationic MBs in DNA delivery, it enhanced UMGD efficiency even at low MB
doses. [4] Dr. Zhang’s group successfully used mannosylated lycorine modified lipid nano-emulsion
formulation (M-LYC-OA-LNEs) for tumor targeting.
The findings from their experiment illustrated that
this formulation could be a promising delivery system
for targeted delivery of lycorine in the diagnosis and
treatment of cancer. [5] In Dr. Gu and his colleagues’
work, two types of liposomes with charged and
PEGylated cholesterols (anionic and cationic) were
synthesized to verify the possible effects of cholesterol
charge, surface shielding and chemical nature in the
liposome. With the help from fluorescence and other
images, the in vivo anti-tumor effect experiments confirmed that charged liposomes presented much higher tumor inhibition effect than neutral liposomes. This
report of anti-cancer effect using charged cholesterol
liposome with/without PEGylation may provide
deeper understanding on the liposome formulation,
which is critical for liposome associated drug research
and development. [6]
All together this special issue reported the front
line findings in the field of IGDD. The achievements
in theranostics will encourage not only the quick diagnosis on disease but also facilitate the treatment
strategy from generalized medicine towards personalized regimen. We sincerely appreciate all the efforts
from authors for their contribution and experience
sharing. All these accomplishment will definitely
push theranostics concept in the world of pharmaceutical sciences and drug delivery into a new level.
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